Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss Per Share of Common Stock

Loss Per Share of Common Stock

3 Months Ended

Mar. 31, 2024

The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net loss per share computations:


	Three Months Ended March 31, (Unaudited)
		2024		2023
Basic EPS and diluted EPS:

Loss (Numerator)
Net loss		$	(5,019,531)	$	(5,167,520)

Shares (Denominator)
Weighted average common shares outstanding(1)		27,999,901		3,767,578
Per-Share Amount		$	(0.18)	$	(1.37)

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:


	Three Months Ended March 31, (Unaudited)
		2024	2023 (1)
Stock options		1,201,398	175,733
Warrants		3,280,940	708,373
Unvested restricted stock units		503,444	10,667
Unvested restricted stock		5,000	—
Convertible Debt		968,922	—

___________________

(1) Previously reported outstanding shares of common stock equivalents were adjusted for the effects of the reverse stock split at a ratio of one-for-two hundred and fifty (1-for-250). The reverse stock split was transacted on September 6, 2023.